We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Starpharma Signs Cancer Drug Agreement with AstraZeneca


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Starpharma Signs Cancer Drug Agreement with AstraZeneca"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Starpharma Holdings Ltd today announced the signing of an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology.

The primary objective of the program is to assess the suitability of the dendrimer constructs for particular applications within the cancer field.

The identity of the anti-cancer molecules to be studied is covered by confidentiality restrictions, but Starpharma notes that the arrangement does not relate to docetaxel or to dendrimer conjugates of docetaxel. Further details of the arrangement between the parties were not disclosed.

Advertisement